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Background: Chronic neuropathic pain (NP) is a complex disease that results from
damage or presumed damage to the somatosensory nervous system. Current treatment
regimens are often ineffective. The major impediment in developing effective treatments
is our limited understanding of the underlying mechanisms. Preclinical evidence suggests
that glial changes are crucial for the development of NP and a recent study reported
oscillatory activity differences within the ascending pain pathway at frequencies similar
to that of cyclic gliotransmission in NP. Furthermore, there is evidence that glial
modifying medications may be effective in treating NP. The aim of this Phase I open-
label clinical trial is to determine whether glial modifying medication palmitoylethano-
lamide (PEA) will reduce NP and whether this is associated with reductions in oscillatory
activity within the pain pathway.
Methods: We investigated whether 6 weeks of PEA treatment would reduce pain and infra-
slow oscillatory activity within the ascending trigeminal pathway in 22 individuals (17
females) with chronic orofacial NP.
Results: PEA reduced pain in 16 (73%) of the 22 subjects, 11 subjects showed pain
reduction of over 20%. Whilst both the responders and non-responders showed reductions
in infra-slow oscillatory activity where orofacial nociceptor afferents terminate in the
brainstem, only responders displayed reductions in the thalamus. Furthermore, functional
connections between the brainstem and thalamus were altered only in responders.
Conclusion: PEA is effective at relieving NP. This reduction is coupled to a reduction in
resting oscillations along the ascending pain pathway that are likely driven by rhythmic
astrocytic gliotransmission.
Keywords: infra-slow oscillations, astrocytes, connectivity, thalamus, imaging
Significance statement
In this investigation, we have tested this hypothesis by conducting a Phase I
clinical trial to determine the effectiveness of a glial modulator, palmitoy-
lethanolamide (PEA) on ongoing pain intensity and oscillatory brain activity.
We found that after 6 weeks of PEA, ongoing was significantly reduced in 16
of 22 subjects and that this reduction was significantly correlated to changes in
infra-slow oscillatory activity within the ascending pain pathway. These data
provide the first human evidence that a substance that can reduce glial
activation can relieve pain without side effects, and that this is associated
with a reduction in ongoing patterns of neural activity in pain pathways that
are consistent with the idea that glial transmission maintains chronic neuro-
pathic pain.
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Introduction
Chronic neuropathic pain (NP) is a complex disease state that
results from damage or presumed damage to the somatosen-
sory nervous system. Current treatment regimens such as
non-steroidal anti-inflammatory medication, tricyclic antide-
pressants and anticonvulsants are often ineffective and have
significant side effects and consequently, many individuals
suffer with considerable pain for years or even decades. The
major impediment in developing more effective treatment
regimens for NP is our limited understanding of the mechan-
isms responsible for the development andmaintenance of NP
following injury.
Critically, NP is not associated with prolonged activity
increases in the classic “pain pathways” but instead is asso-
ciated with altered brain rhythm. This altered rhythm is
characterized by increased thalamic burst firing, thalamocor-
tical power and infra-slow oscillations (<0.1 Hz) along the
ascending pain pathway.1–3 Whilst it is not known how these
altered rhythms are generated, the infra-slow oscillation
increases occur at approximately the same frequency range
as calciumwaves in astrocytes, ie, 0.03–0.06 Hz.4 Astrocytes
can modulate synaptic activity by the release of gliotransmit-
ters and there is preclinical and postmortem human evidence
of prolonged astrocyte activation in the dorsal horn/spinal
trigeminal nucleus (SpV) in NP.5,6 Furthermore, preclinical
studies have shown that following nerve injury, increased
astrocyte activation is associated with allodynia and
hyperalgesia7,8 and blocking astrocyte activation reverses
this allodynia and hyperalgesia.9–11
PEA is a naturally occurring fatty acid amide that belongs
to the N-acetylethanolamine family. It is thought that PEA
targets alpha peroxisome proliferator-activated receptors
(PPAR-α),12–16 which are expressed on neurons and
astrocytes17,18 and are activated as a response to nerve
damage.6,10 Interestingly, a recent case study found that in
an individual without the ability to breakdown PEA, elevated
serum PEAwas associated with pain insensitivity, implying
that endogenous PEA plays a role in pain processing.19 In
addition, there have been numerous clinical trials exploring
the effects of PEA in various pain states and most show pain
reductions and critically, PEA has reportedly no serious side
effects.20 If PEA can reduce NP without any serious side
effects, this would be a major advance in the way in which
we treat chronic NP and significantly reduce the economic
and social burden of this debilitating condition. The aim of
this investigation is to provide evidence that PEA reduces the
intensity of ongoing pain and reverses the increase in infra-
slow oscillatory activity within the primary afferent synapse
in individuals with chronic NP.
Methods
Subjects
Twenty-two subjects with chronic orofacial NP (17 females;
mean±SEMage, 50.5±3.0 years) were recruited for the study.
NP subjects were diagnosed using the Liverpool criteria as
having posttraumatic neuropathy.21 Subjects were excluded
if they had any psychiatric conditions, any other pain condi-
tions or did not meet standard magnetic resonance imaging
(MRI) inclusion criteria.
Protocol approval and registration
Informed written consent was obtained for all procedures
according to the Declaration of Helsinki, and the Human
Research Ethics Committees of the University of Sydney
approved the study. This trial was registered with the
Australian New Zealand Clinical Trials Registry with the
trial ID: ACTRN12618001637235.
Study design
All subjects completed two MRI sessions, 6 weeks apart.
During the 7 days prior to the start of PEA treatment and
the first MRI session, subjects kept a pain diary in which
they recording the intensity of their ongoing pain, three
times a day. Subjects rated the intensity of their pain using
a 10 cm horizontal VAS, with 0 indicating “no pain” and
10 indicating “the most intense imaginable pain”. These
21 pain intensity scores were then averaged over the 7-day
period to create a mean pain intensity score prior to PEA
treatment. On the day of their first MRI scanning session,
each NP subject outlined the location of their ongoing pain
on a standard drawing of the head and completed a McGill
Pain Questionnaire. Following their first MRI scanning
session, each NP subject began PEA treatment and at 6
weeks, a second MRI session was performed. During the 7
days prior to the second MRI scan, subjects kept another
pain diary recording the intensity of their ongoing pain. On
the day of the second MRI scan, subjects outlined the
location of their ongoing pain on a standard drawing of
the head and completed a McGill Pain Questionnaire.
Interventions
NP subjects obtained the PEA from Visionary Health
Compounding Chemist, Newcastle, Australia in the form
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of 300 mg capsules, with dosage individualized between
600 and 900 mg, three times a day. PEA was provided to
the compounding chemist in a naive form and was ground
with a mortar and pestle until a fluffy consistency was
obtained. Analysis of the final PEA revealed that more
than 75% was in an ultra-micronized state (<10 microns)
with the remaining in a micronized state with particles
between 10 and 50 microns in size. The PEA was then
placed into gelatine capsules for oral consumption.
MRI acquisition
For each MRI scanning session, NP and control subjects
lay supine on the bed of a 3 Tesla MRI scanner (Achieva;
Phillips) with their head immobilized in a tight-fitting head
coil. With each subject relaxed and at rest, a series of 180
gradient echo echo-planar functional MRI (fMRI) image
volumes using blood oxygen level-dependent contrast
were collected. Each image volume contained 35 axial
slices covering the entire brain (field of view 240×240
mm; matrix size 80×78; slice thickness 4 mm; repetition
time 2000 ms; echo time 30 ms; flip angle 90°). Following
this, a series of 108 pseudocontinuous arterial spin label-
ing (pCASL) images containing 50 axial slices covering
the entire brain was collected (54 label/control image
pairs, field of view 240×240 mm; matrix size 100×100;
slice thickness 3 mm; repetition time 5084 ms, echo time
12.7 ms, labelling time 1600 ms, slice time 36.6 ms,
labeling efficiency 0.85, blood T1 relaxation time
1667ms). Finally, in each subject, a high-resolution 3D
T1-weighted anatomical image set covering the entire
brain was also collected (turbo field echo; field of view,
250×250 mm; matrix size 288×288; slice thickness 0.87
mm; repetition time 5600 ms; echo time 2.5 ms; flip
angle 8°).
Pain intensity changes
At the completion of the 6-week treatment period, NP
subjects’ pain intensity changes were assessed. To explore
the association between pain intensity reductions and
changes in brain function, NP subjects were divided into
those that responded to PEA treatment, ie, responders:
>20% reduction in pain intensity, and non-responders:
<20% reduction in pain intensity. To determine the effect
size of changes in pain intensity in responders and non-
responders, Cohen’s d was calculated. This is used to
determine whether the effect size is small (d=0.2), medium
(d=0.5) or large (d=0.8).22 Changes in pain distributions
before and after treatment for each subject in the two
groups separately were determined using a paired t-test
(p<0.05, Bonferroni corrected).
MRI analysis; infra-slow oscillations
Using SPM12,23 all functional magnetic resonance images
were motion corrected, global signal drifts removed24 and
co-registered to each individual’s T1-weighted image set.
Each subject’s T1-weighted anatomical image was then spa-
tially normalized to a template in Montreal Neurological
Institute (MNI) space and the parameters applied to the
fMRI image sets. All images were then spatially smoothed
(6 mm full-width half-maximum [FWHM] Gaussian filter).
In those subjects with pain restricted to the left side of the
face (n=12), resting fMRI scans were reflected across the
midline so that, in all subjects, the right side was ipsilateral to
ongoing pain. To perform a brainstem-specific analysis, the
fMRI images were cropped to include only the brainstem and
cerebellum and amask of these regions created automatically
using the SUIT toolbox.25 These brainstem/cerebellum
masks were then manually adjusted to accurately encompass
the brainstem and cerebellum only. Using this mask, fMRI
brainstem images were spatially normalized to the Spatial
Unbiased Infratentorial Template in MRI space and spatially
smoothed using a 3 mm FWHM Gaussian filter.
To determine regional changes in infra-slow oscillation
power, we used the SPM toolbox REST26 to calculate the
sum of amplitudes of low-frequency fluctuations (ALFF) in
the frequency band 0.03–0.06 Hz for the brainstem only and
wholebrain fMRI image sets. ALFF values were then divided
over the entire frequency range to obtain fractional ALFF
(fALFF) value for each voxel. Using the wholebrain and
brainstem only images, the effects of PEA treatment on
fALFF were determined in all 22 NP subjects using a paired
random effects procedure. In addition, the effects of PEA on
fALFF values were determined in the responder and non-
responder groups separately using paired random effects pro-
cedures. Following an initial threshold of p<0.001, small
volume corrections were used to account for the effects of
multiple comparisons (p<0.05 Bonferonni corrected). For
each analysis, the six movement parameters derived from the
realignment step and signal intensity derived from a 3 mm
sphere located in the fourth ventriclewere included as nuisance
variables. For each significant cluster, fALFF values were
extracted from each subject and the mean (±SEM) plotted.
We also determined the relationships between changes in
fALFF over the treatment period and the associated change
in pain intensity. In each voxel, the change in fALFF during
PEA treatment (pre-post PEA) was calculated and voxel-by-
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voxel correlations between this fALFF change and the per-
cent change in pain intensity were performed for the
responder and non-responder groups separately (movement
and CSF signal included as nuisance variables). Following an
initial threshold of p<0.001, small volume corrections were
used to account for the effects of multiple comparisons
(p<0.05 Bonferonni corrected).
In addition, we also performed a functional connectivity
analysis using a seed placed into the region of the SpV. This
seed was based on the results of the fALFF comparison pre
compared to post-PEA treatment in the responder group.
Signal intensity changes from the SpV were extracted in
each individual subject and correlations between this signal
and every voxel in the brainstem only and wholebrain
image sets determined (movement parameters and CSF
signal included as nuisance variables). Connectivity values
between the SpV and the ventroposterior (VP) thalamus (a
cluster based on the results from the fALFF analysis) were
extracted for each subject and significant differences
between pre- and post-PEA treatment and between respon-
der and non-responder groups determined using paired and
two group t-tests (p<0.05, Bonferroni corrected).
MRI analysis; resting blood flow
All pCASL image sets were realigned, co-registered to
each individual’s T1-weighted image set, the label and
control images averaged and a mean cerebral blood flow
(CBF) image created using the subtraction method using
the ASL toolbox.27 Wholebrain and brainstem-only CBF
maps were then normalized into MNI space and smoothed
in the same manner as the fMRI images sets. For each
significant cluster derived from the fALFF analysis, blood
flow values were extracted for each subject and the mean
values plotted for each subject before and after treatment
and significance differences determined using paired t-
tests (p<0.05, Bonferroni corrected).
Data availability statement
Anonymized data can be shared by request from any
qualified investigator.
Results
Psychophysics
Prior to PEA treatment, NP subjects had ongoing pain of 4.5
±0.4 (mean±SEM) VAS, pain duration of 4.1±1.3 years and
5 NP subjects were taking Serotonin-Noradrenaline
Reuptake Inhibitors. PEA treatment resulted in no reported
side effects and an overall reduction in ongoing pain inten-
sity of 0.7±0.4 VAS or 21.2±11.4% (Table 1). Overall, PEA
treatment reduced pain in 16 (73%) of the 22 NP subjects.
Dividing subjects into responders (>20% pain reduction) and
non-responders (<20% pain reduction) resulted in 11 subjects
as responders and 11 as non-responders (Figure 1A).
Responders had an average pain reduction of 2.1±0.3 VAS
or 61.9±7.2% and non-responders an overall increase of 0.6
±0.5 VAS or 19.6±12.8% (Figure 1B). Cohen’s d showed
that as a whole group, the effect size was small (d=0.3).
However, in the responders, the effect size is large (d=1.8)
and in the non-responders, the effect size is small (d=0.3).
Although there was a significant difference in the magnitude
of pain intensity reduction between groups, there was no
significant change in the area of pain in response to PEA
treatment in either group (mean±SEM pixels: responders
pre-PEA 1143±494, post-PEA 416±187; non-responders
pre-PEA 7935±4325, post-PEA 6890±3841, both p>0.05)
(Figure 1C).
In addition to differences in the responsiveness to PEA
treatment, responders had a significantly lower pain inten-
sity (3.4±0.3 VAS) compared with non-responders (5.6
±0.7 VAS) prior to PEA treatment (p<0.05). There was,
however, no significant difference in pain duration
(responders 3.0±1.5 years, non-responders 5.2±2.1 years,
p>0.05) or the area of perceived pain (responders 1143
±494 pixels, non-responders 7935±4325 pixels, p>0.05)
between groups before PEA treatment.
Infra-slow oscillatory activity and
functional connectivity
PEA treatment had a significant effect on regional resting
infra-slow oscillations in both the responder and non-respon-
der groups. Remarkably, in both the responder and non-
responder groups, PEA treatment significantly reduced
ongoing infra-slow oscillatory activity in the region encom-
passing the ipsilateral (to side of ongoing pain) SpV, ie, the
region where nociceptor afferents from the area of ongoing
pain terminate (fALFF 0.03–0.06 Hz: responders pre-PEA
1.03±0.06 post-PEA 0.79±0.05; non-responders pre-PEA
1.14±0.07 post-PEA 0.92±0.06; Figure 2, Table 2). Whilst
both responders and non-responders displayed reduced oscil-
latory activity in SpV, only the responders also displayed
significant oscillatory activity reductions in the upstream
target of SpV, ie, in the region of the VP thalamus (respon-
ders pre-PEA 0.98±0.10 post-PEA 0.84±0.08; non-respon-
ders pre-PEA 0.99±0.06 post-PEA 0.98±0.05; Figure 3).
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Plots of individual subject oscillatory power pre- and post-
PEA shown in Figure 3 highlight the consistency of these
changes in the SpV in both responder and non-responder
groups and in the thalamus in responders. In addition to
changes in the ascending trigeminal pathway, the non-
responders displayed oscillation decreases in the midbrain
including the region of the periaqueductal gray matter
(PAG), the anterior and posterior cingulate cortices and
increases in the precuneus. Furthermore, in the responders,
PEA treatment also resulted in oscillation decreases in the
dorsolateral pons, hippocampus, lateral prefrontal cortex and
precuneus.
The extraction of fALFF values from the SpV and VP
thalamus confirmed that PEA treatment resulted in signifi-
cant reductions in infra-slow oscillations in the SpV in
both responders and non-responders and reductions in the
VP thalamus in the responder group only (Figure 3).
Furthermore, only responders displayed a significant
change in resting connectivity between the SpV and VP
thalamus in response to PEA treatment. That is, prior to
PEA treatment there was a significant signal covariation
between the SpV and VP thalamus in responders which
was subsequently completely eliminated by PEA treatment
(SpV-VP thalamus connectivity: responders pre-PEA 0.18
±0.07 post- PEA 0.01±0.04, p<0.05). In contrast, PEA
treatment had no effect on SpV-VP thalamus connectivity
in the non-responders (pre-PEA 0.09±0.06 post-PEA 0.04
±0.05, p>0.05).
In addition, the change in infra-slow oscillations within
the ascending trigeminal pathway was not associated with
changes in overall activity levels as evidenced by no
change in resting blood flow in either the SpV (mL/min/
100 g: responders pre-PEA 98.7±7.9 post-PEA 87.4±10.7,
non-responders pre-PEA 79.9±10.5 post-PEA 81.8±9.4,
Responders
Pre-PEA treatment
Responders
Responders
Pre-PEA
Post-PEA Post-PEA
P
re
-P
E
A
P
re
-P
E
A
P
os
t-P
E
A
P
os
t-P
E
A
Pre-PEANon-responders
Non-
responders
Post-PEA treatment
Non-responders
Pre-PEA treatment Post-PEA treatment
Figure 1 Subject psychophysics. (A) Daily pain intensity ratings in each of the 22 patients pre-palmitoylethanolamide (PEA) treatment and post-PEA treatment separated
into responders (>20% pain reduction) and non-responders (<20% pain reduction). Pain intensity was rated three times daily on a 10 cm VAS; (B) mean (±SEM) pain
intensity ratings pre- and post-PEA in the responder (n=11) and non-responder (n=11) groups; (C) areas of ongoing pain pre- and post-PEA in the responder and non-
responder groups.
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p>0.05) or the VP thalamus (responders pre-PEA 43.9±6.1
post-PEA 54.8±8.5, non-responders pre-PEA 28.9±5.4
post-PEA 45.8±8.6, p<0.05).
Correlations between changes in pain intensity and
changes in infra-slow oscillations revealed significant clus-
ters in the SpV and VP thalamus overlapping those sig-
nificant clusters revealed in the pre- versus post-fALFF
analysis (Figure 4). In responders, the magnitude of the
decrease in infra-slow oscillations was significantly posi-
tively correlated with a decrease in pain intensity during
PEA treatment in both the region of the SpV (r=0.83,
p<0.05) and VP thalamus (r=0.93, p<0.05). In contrast,
no significant correlations occurred in non-responders in
the SpV (r=0.04, p>0.05) or VP thalamus (r=0.28,
p>0.05).
Discussion
This investigation describes the effects of PEA on ongoing
pain and brain function in patients with chronic orofacial NP.
PEA reduced pain intensity in almost 75% of patients with
50% of all patients exhibiting an overall decrease of over
20%with no recorded side effects. Additionally, PEA altered
regional brain function by reducing infra-slow oscillatory
activity in the ascending trigeminal pain pathway. More
specifically, our results show that altered activity patterns
and connectivity within the trigeminal pathway are asso-
ciated with an individual’s pain relief responsiveness to
PEA treatment. Whilst three previous investigations have
reported NP relief as a result of PEA treatment,28–30 this is
the first to show that the effectiveness of PEA is associated
with altered activity patterns in the ascending pain pathway.
Critically, like our study, no clinical trial using PEA for pain
or any other condition has reported significant side effects.
We have previously shown that chronic orofacial NP is
associated with an increase in resting infra-slow oscilla-
tions along the ascending trigeminal pain pathway, includ-
ing the SpV, VP thalamus, thalamic reticular nucleus and
primary somatosensory cortex.31,32 Given that there is
preclinical and human postmortem evidence of chronic
astrogliosis in the SpV/dorsal horn in individuals with
NP and that the oscillations were at the same approximate
frequencies in which astrocyte calcium and
Figure 2 Effects of palmitoylethanolamide (PEA) on infra-slow oscillations. (A) Differences in fractional amplitude of low-frequency fluctuations (fALFF) pre-PEA compared
with post-PEA treatment on non-responders. Significant increases (hot color scale) and decreases (cool color scale) in fALFF are overlaid onto a series of axial and sagittal
T1-weighted anatomical slices. Slice locations in Montreal Neurological Institute space are indicated at the top right of each slice. (B) Differences in fALFF pre-PEA compared
with post-PEA treatment in responders. Note that fALFF decreased in the spinal trigeminal nucleus (SpV) in both responders and non-responders and in the ventroposterior
(VP) thalamus only in responders.
Abbreviations: ACC, anterior cingulate cortex; dlPons, dorsolateral pons; PAG, midbrain periaqueductal gray matter; PCC, posterior cingulate cortex.
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gliotransmission release have been recorded, we speculate
that these oscillatory activity increases were the result of
chronic astrogliosis. Astrocyte calcium can propagate to
neighboring astrocytes either directly through connecting
channels or indirectly through the release of gliotransmit-
ters to produce synchronous oscillatory gliotransmitter
release.33,34 This oscillatory astrocyte function can elicit
long-lasting NMDA-mediated currents in surrounding
neurons4 and there is recent evidence that astrocytes can
elicit long-lasting increases in neural firing.35 We have
proposed that following nerve injury, excess activity
within primary afferent neurons results in neural death
and elicits astrocyte activation at the primary afferent
synapse. This results in more regular and increased oscil-
latory gliotransmitter release and increased infra-slow
neural oscillations which are transferred along the ascend-
ing pain pathway. The recurrent nature of thalamocortical
circuits results in self-sustaining thalamocortical dysrhyth-
mia, paroxysmal events and the constant perception of
pain.1,2,36 Interestingly, recent preclinical investigations
have shown a gender divide regarding the main cells
involved in chronic NP. In males, microglia play a large
role in the initiation and maintenance of neuropathic37,38
pain and in our investigation, only one in the four males
enrolled in the study responded to the treatment.
Furthermore, in the previous investigation on infra-slow
oscillatory activity in patients with orofacial NPn, 82% of
the subjects were females. Hence, it is more likely that
astrocytes might be the driving force of infra-slow oscilla-
tory activity in the female population than it is in the male.
Consistent with this hypothesis, the present investigation
found that PEA administration resulted in a reduction in both
pain intensity and oscillatory activity within the ascending
trigeminal pain pathway. PEA is abundant in the central
nervous system and there is preclinical evidence that NP is
associated with reductions in PEA levels in the ipsilateral
spinal cord and that these levels increase following pain
relief.39 PEA is produced by glial cells40 and has been
studied primarily for its anti-inflammatory and neuroprotec-
tive effects.16,20,41 Whilst PEA can exert its effects via multi-
ple mechanisms, it is thought that the main target of PEA is
the peroxisome proliferator-activated receptor alpha (PPAR-
Table 2 Montreal Neurological Institute (MNI) coordinates, cluster size and t-score for regions of significant differences in fractional
amplitude of low-frequency fluctuations between pre- and post-palmitoylethanolamide treatment
Brain region MNI coordinate Cluster size t-score
x y z
Responders
Pre>post-palmitoylethanolamide treatment
Dorsolateral pons 6 −30 −19 15 4.62
Spinal trigeminal nucleus 10 −44 −53 5 5.40
Left ventroposterior thalamus −14 −22 6 10 4.18
Right dorsal thalamus 18 −22 12 17 4.76
Anterior cingulate cortex 4 26 32 10 6.16
Hippocampus −32 −12 −22 19 7.17
Precuneus −10 −44 48 15 5.24
−4 −66 26 9 3.74
Posterior parietal association cortex 52 −54 24 15 3.93
Ventrolateral prefrontal cortex −46 30 −10 16 5.70
Post>pre-palmitoylethanolamide treatment
Caudate nucleus −14 20 0 10 4.32
Cerebellar cortex −4 −74 −16 23 4.25
Correlations with pain
increases
Spinal trigeminal nucleus 8 −46 −55 3 3.89
Ventroposterior thalamus −18 −26 8 18 6.36
Anterior cingulate cortex −8 34 20 17 8.78
Decreases −48 26 14 26 5.95
Dorsolateral prefrontal cortex −44 26 30 12 9.34
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α).12,13,15,16,42 PPAR-α is an isotope of the PPARs that can
affect the transcription of a number of genes and is expressed
by astrocytes and it is possible that astrocytes play a role in
the anti-nociceptive effects of PEA through a PPAR-α
pathway.16 Critically, it has been shown to blunt astrocyte
activation in vitro and improve neuronal survival through
selective PPAR-α activation.43 Indeed, PEA fails to exert its
anti-nociceptive effects in PPAR-α knockout mice.12–14,42,44
We found that in all patients, oral administration of
PEA resulted in significant reductions in infra-slow oscil-
lations specifically at frequencies similar to those of astro-
cyte calcium waves (0.03–0.06 Hz) in the ipsilateral SpV.
However, only in individuals in which PEA evoked a
significant reduction in pain did a similar reduction in
neural oscillations also occur in the VP thalamus.
Furthermore, PEA treatment eliminated the resting neural
covariation between SpV and VP thalamus only in
responders. These results suggest that whilst PEA blunts
the increase in resting neural oscillatory activity at the
region of the primary afferent synapse in all patients,
only when this reduction is then transferred to higher
brain centers such as the thalamus does an analgesia result.
Indeed, only in responders was the reduction in neural
oscillation power significantly correlated to the reduction
in pain, ie, the greater the reduction in oscillations the
greater the reduction in ongoing pain. This is entirely
consistent with the results from an experimental animal
model of NP in which infra-slow oscillatory activity in the
VP thalamus was eliminated by severing the connection
between the primary afferent synapse and the thalamus.45
Furthermore, PEA decreases infra-slow oscillatory activity
in the PAG which makes up part of the descending pain
modulation pathway. In nerve injury models, there is
increase in astrocyte activity in the PAG and other regions
Figure 3 Effects of palmitoylethanolamide (PEA) on ascending pain pathway. To the right are plots of mean (±SEM) fractional amplitude of low-frequency fluctuations (fALFF)
and cerebral blood flow (CBF) in responders (blue) and non-responders (green), pre- and post-PEA treatment. Individual subject values pre- and post-PEA are indicated in
the fALFF plots by the white lines between the colored bars indicating the mean (±SEM). Note that both the responders and non-responders have a significant reduction in
infra-slow oscillations in the spinal trigeminal nucleus, but only the responders have a decrease in the ventroposterior thalamus. In contrast, there are no changes in CBF. The
regions in which fALFF decreases as a consequence of PEA treatment are color coded blue (responders) and green (non-responders) and overlaid onto axial T1-weighted
anatomical slices. To the left of these overlays are plots of mean (±SEM) resting functional connectivity between the spinal trigeminal nucleus and ventroposterior thalamus.
Individual subject values pre- and post-PEA are indicated in the functional connectivity plots by the white lines between the colored bars. Note that functional connectivity
decreases significantly following PEA treatment in the responders only. *p<0.05 derived from voxel-by-voxel analysis; #p<0.05 derived from two-sample t-test.
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of the descending pain modulation pathway such as the
rostroventral medulla.46,47 However, in the results of this
investigation, the non-responders had decreases in infra-
slow oscillatory activity in the PAG only, which may not
be sufficient to modulate the descending pain pathway
enough to produce pain intensity decreases.
Whilst we suggest that in individuals with chronic
NP, PEA produces pain relief via its effects on astrocyte
function, PEA may also exert effects via a number of
other mechanisms. Within the central nervous system,
PPAR-α receptors act via two main mechanisms; a rapid
effect which involves activation of calcium-dependent
potassium channels which has a silencing effect on
neuronal firing15 and a slower effect which is comprised
of neurosteroid de novo synthesis which increases allo-
pregnanolone production.48,49 Allopregnanolone is a
positive allosteric modulator of GABA action and
slows the rate of recovery of GABA receptors.50,51 In
addition to a potential action on neuronal GABA recep-
tors, PEA may influence GABA receptors on astrocytes,
which when activated can increase intracellular calcium
levels.52 Interestingly, astrocyte calcium wave propaga-
tion is dependent upon mechanisms which include the
removal of excess calcium by mitochondria to prevent
IP3 receptor desensitization.53,54 It is possible that PEA
increases calcium concentrations thereby reducing the
propagation of astrocyte calcium waves and associated
gliotransmission. Interestingly, all of the five patients in
this investigation that were also taking selective seroto-
nin reuptake inhibitors (SSRIs) reported pain relief,
although four of these subjects reported reductions that
were small and were categorized as non-responders.
Whilst the precise mechanism of SSRIs is not known,
it has been shown that they can increase the expression
of GABAB receptors and alter astrocyte function
directly, evoking astrocyte calcium transients in an
often oscillatory manner, even when neural activity is
inhibited.55,56 Given this, it is possible that SSRIs par-
tially counteract the mechanism of PEA and thus reduce
its overall analgesic effectiveness.
Figure 4 Relationships between changes in pain intensity and infra-slow oscillations as a result of palmitoylethanolamide (PEA) treatment. Significant positive linear
relationships between changes in ongoing pain and fractional amplitude of low-frequency fluctuations (fALFF) in the thalamus and medulla are shown overlaid onto axial T1-
weighted anatomical slices for the responder group only (yellow shading). Note no such relationship occurred in the non-responders. Slice locations in Montreal
Neurological Institute space are indicated at the top right of each slice. The location of significant decreases in infra-slow oscillations (ISO) pre- versus post-PEA are
also shown (light blue shading); note the overlap within the spinal trigeminal nucleus and ventroposterior thalamus. To the right are plots of change in fALFF versus percent
change in pain for the SpV and VP thalamus cluster in responders and non-responders pre- versus post-PEA treatment. In responders, the greater the reduction in fALFF the
greater the reduction in pain intensity.
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It is also a possibility that PEA may act on other targets
in the nervous system such as cannabinoids in neurons and
astrocytes,57,58 PPAR-γ59 or mast cells60 to reduce pain.
Whilst these and other targets are possible, we suggest
that PEA most likely targets PPAR-α in individuals with
NP. As mentioned above, PEA fails to exert its anti-noci-
ceptive effects in PPAR-α knockout mice. Furthermore, a
recent study in the spared nerve injury model of NP found
that whilst PEA reversed the development of thermal hyper-
algesia, mechanical allodynia and cognitive impairment in
wild-type mice, it had no effect in PPAR-α knockout mice.-
61 Similarly, in the chronic constriction model of NP, PEA
treatment prevented the development of hyperalgesia and
reduced the inflammatory changes in the damaged nerve,
changes that were not seen following PEA treatment in
PPAR-α knockout mice.62 It is possible that the effects of
PEA on PPAR-α may also involve more indirect targets
since it was shown that PEA increases cannabinoid receptor
type 2 mRNA and protein expression via PPAR-α activation
in cultured rat microglia and human macrophages.63 Whilst
a role for PEA effects via microglial actions may exist, it is
likely to occur in only the onset phase of NP since there is
evidence that in chronic NP, microglial activation subsides
following an initial increase whereas astrocyte activation
persists.64,65
Interestingly, the midbrain periaqueductal gray matter
and the anterior cingulate cortex have been shown to mod-
ulate cannabinoid-induced analgesia.66,67 The non-respon-
ders showed reductions in infra-slow oscillations in the
PAG and the anterior cingulate cortex and no such change
was evident in the responders, which may be contributing to
the lack of change in pain intensity in the non-responders.
Furthermore, PEA has been shown to reduce pain and nega-
tive affect through the endocannabinoid and glutamatergic
system in a number of pain states.68–70 It is possible that PEA
acts on multiple receptors in a number of sites to attenuate
inflammation and pain, and reduce negative affect associated
with nerve damage and chronic pain.60 In the non-respon-
ders, although there was no significant decrease in pain
intensity, there was a significant decrease in infra-slow oscil-
latory activity in the anterior cingulate and the insular cortex.
These regions are involved in the affective state71 and while
the affective measures were not collected, it is possible that
PEA modulated negative affect states in the non-responders
without affecting the pain scores.
A limitation of this study is that this was an open-label
clinical trial and we did not control for the potential effects of
placebo. However, it is unlikely that the decrease in pain
intensity in the responders was solely due to the placebo effect.
In fact, a Cochrane meta-analysis showed that over a number
of investigations, the effect size of a placebo response, mea-
sured as Cohen’s d, is 0.27.72 In this investigation, the effect
size as a whole group is 0.3, which may indeed be due to a
placebo effect. However, in the responders only, the effect size
is 1.8, suggesting that the response in the responders is not a
placebo effect. Nonetheless, the decreases in pain intensity
correlate with a change in neural activity in the responders as
a result of PEA. A future larger clinical trial investigating the
effects of PEA on NP and the associated changes in brain
function is needed.
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